Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.
JAMA Netw Open. 2020 Oct 1;3(10):e2021182. doi: 10.1001/jamanetworkopen.2020.21182.
Variations across regions for managing acute myocardial infarction (AMI) in China are little understood.
To evaluate geographic variation and its change with time in treatment process and outcomes for patients with AMI.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the Patient-Centered Evaluative Assessment of Cardiac Events-Retrospective AMI project in 2001, 2006, 2011, and 2015 in 153 randomly selected hospitals across China. Patients were hospitalized for AMI. Data were analyzed from October 1 to October 31, 2019.
Hospitalization in 3 geographic regions (Eastern, Central, and Western) stratified according to China's official definition.
Process of care measures included reperfusion therapies, aspirin, clopidogrel, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins. Therapy use was analyzed among patients who were clinically eligible without contraindications (considered as ideal candidates for treatments). Outcome measures included in-hospital mortality and 5-day mortality. Mixed models were used to assess the regional disparities and time-region interactions in those measures, adjusting for patient characteristics.
In 153 hospitals across China, 27 046 patient hospitalizations for AMI were sampled. There was a significant difference across regions in process of care and the odds ratio (OR) of delivering any 1 of the 6 treatments to an ideal patient was 0.83 (95% CI, 0.76-0.91; P < .001) for the lowest region compared with the highest region. The variation between the 2 higher regions narrowed (time-by-Eastern region interaction: OR, 0.83; 95% CI, 0.76-0.91; P < .001). The region with the highest in-hospital mortality had 1.46 times greater in-hospital mortality (95% CI, 1.07-2.00; P < .001) than the lowest region and the region with the highest 5-day mortality had 1.52 times greater 5-day mortality (95% CI, 1.09-2.11; P = .04) than the lowest region. The geographic variation in mortality did not change over time.
In this study, significant geographic variations in process of care and outcomes were found to persist in China; further targeted and region-based approaches to AMI management are warranted.
中国在急性心肌梗死(AMI)管理方面的区域差异尚未得到充分了解。
评估患者 AMI 治疗过程和结局的地域差异及其随时间的变化。
设计、地点和参与者:本横断面研究使用了来自 2001 年、2006 年、2011 年和 2015 年中国 153 家随机选定医院的患者中心评估心脏事件回顾性 AMI 项目的数据。患者因 AMI 住院。数据分析于 2019 年 10 月 1 日至 10 月 31 日进行。
根据中国官方定义,按地理区域(东部、中部和西部)分层的住院治疗。
治疗过程措施包括再灌注治疗、阿司匹林、氯吡格雷、β-受体阻滞剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂以及他汀类药物。对没有禁忌症(被认为是治疗的理想人选)的临床合格患者进行治疗使用分析。结局指标包括院内死亡率和 5 天死亡率。使用混合模型评估这些措施的区域差异和时间-区域相互作用,同时调整患者特征。
在中国的 153 家医院中,共抽样了 27046 例 AMI 患者住院治疗。在治疗过程和为理想患者提供 6 种治疗方法中的任何 1 种的可能性方面,与最高地区相比,最低地区的比值比(OR)为 0.83(95%置信区间,0.76-0.91;P<0.001)。两个较高地区之间的差异缩小(东部地区时间交互作用:OR,0.83;95%置信区间,0.76-0.91;P<0.001)。死亡率最高的地区的院内死亡率比死亡率最低的地区高 1.46 倍(95%置信区间,1.07-2.00;P<0.001),死亡率最高的地区的 5 天死亡率比死亡率最低的地区高 1.52 倍(95%置信区间,1.09-2.11;P=0.04)。死亡率的地域差异没有随时间变化。
在这项研究中,发现中国在治疗过程和结局方面存在显著的地域差异;需要进一步采取有针对性和基于地区的 AMI 管理方法。